Sonnenburg C, Muir A C, Criscione L, Kraetz J, Hofbauer K G
Ciba-Geigy Limited, Biological Research Department, Basle, Switzerland.
J Hypertens Suppl. 1985 Dec;3(3):S303-5.
Atrial natriuretic factors (ANF) have both vasorelaxant and natriuretic properties. It has been suggested that their effects on sodium excretion depend on renal vasodilatation. We studied the haemodynamic (ultrasound Doppler flow probes) effects of synthetic atriopeptin II at natriuretic doses in conscious rats. Intravenous injections of atriopeptin II induced a marked, dose-dependent increase in sodium excretion. This was accompanied by a slight reduction in blood pressure (BP) and a transient decrease in renal, mesenteric and aortic blood flow. In contrast, a selective renal vasodilator, CGP 22,979, induced a moderate increase in sodium excretion concomitantly with a rise in renal blood flow. Blood pressure and the other regional flows remained unchanged. These findings suggest that the natriuretic effect of CGP 22,979 is closely related to an increased renal blood flow. Conversely, the natriuresis induced by atriopeptin II is not accompanied by selective renal vasodilatation and appears to be due either to a tubular action or to changes in intrarenal haemodynamics.
心房利钠因子(ANF)具有血管舒张和利钠特性。有人认为它们对钠排泄的作用取决于肾血管舒张。我们研究了合成心房肽II在利钠剂量下对清醒大鼠的血流动力学(超声多普勒血流探头)影响。静脉注射心房肽II可引起钠排泄显著的剂量依赖性增加。这伴随着血压(BP)的轻微降低以及肾、肠系膜和主动脉血流的短暂减少。相比之下,一种选择性肾血管扩张剂CGP 22,979可引起钠排泄适度增加,同时肾血流量增加。血压和其他局部血流保持不变。这些发现表明,CGP 22,979的利钠作用与肾血流量增加密切相关。相反,心房肽II诱导的利钠作用并不伴有选择性肾血管扩张,似乎是由于肾小管作用或肾内血流动力学变化所致。